This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosing, D. R. Articles by Epstein, S. E. Search for Related Content PubMed PubMed Citation Articles by Rosing, D. R. Articles by Epstein, S. E.

Circulation, Vol 60, 1201-1207, Copyright © 1979 by American Heart Association

ARTICLES

Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects

DR Rosing, KM Kent, JS Borer, SF Seides, BJ Maron and SE Epstein

The hemodynamic effects of intravenous verapamil administration were examined in 27 patients with hypertrophic cardiomyopathy. Increasing doses of verapamil produced small increases in heart rate and cardiac output and a significant decrease in systolic blood pressure, but had no significance effect on mean pulmonary artery wedge pressure or left ventricular end-diastolic pressure. The highest dose of verapamil increased heart rate from 72 +/- 3 to 81 +/- 6 beats/min and reduced systolic blood pressure from 118 +/- 8 to 99 +/- 5 mm Hg (p less than 0.005). This dose decreased the basal left ventricular outflow tract gradient from 94 +/- 14 to 49 +/- 14 mm Hg and the average left ventricular outflow tract gradient during the Valsalva maneuver from 76 +/- 5 to 63 +/- 13 mm Hg, during amyl nitrite inhalation from 69 +/- 15 to 39 +/- 13 mm Hg, and during isoproterenol infusion from 108 +/- 29 to 70 +/- 21 mm Hg (p less than 0.01). These results indicate that verapamil can significantly decrease left ventricular outflow obstruction in patients with hypertrophic cardiomyopathy and thus may provide an important new therapeutic agent in the treatment of this disorder.

This article has been cited by other articles:

				M. A. Fifer and G. J. Vlahakes Management of Symptoms in Hypertrophic Cardiomyopathy Circulation, January 22, 2008; 117(3): 429 - 439. [Full Text] [PDF]

				M. Ashidagawa, M. Ohara, and Y. Koide An Intraoperative Diagnosis of Dynamic Left Ventricular Outflow Tract Obstruction Using Transesophageal Echocardiography Leads to the Treatment with Intravenous Disopyramide Anesth. Analg., February 1, 2002; 94(2): 310 - 312. [Abstract] [Full Text] [PDF]

				M. V. Sherrid, G. Pearle, and D. Z. Gunsburg Mechanism of Benefit of Negative Inotropes in Obstructive Hypertrophic Cardiomyopathy Circulation, January 13, 1998; 97(1): 41 - 47. [Abstract] [Full Text] [PDF]

				M. Hamada, Y. Shigematsu, S. Ikeda, Y. Hara, H. Okayama, K. Kodama, T. Ochi, and K. Hiwada Class Ia Antiarrhythmic Drug Cibenzoline : A New Approach to the Medical Treatment of Hypertrophic Obstructive Cardiomyopathy Circulation, September 2, 1997; 96(5): 1520 - 1524. [Abstract] [Full Text]

				E. D. Wigle, H. Rakowski, B. P. Kimball, and W. G. Williams Hypertrophic Cardiomyopathy : Clinical Spectrum and Treatment Circulation, October 1, 1995; 92(7): 1680 - 1692. [Full Text]

				B. Heric, B. W. Lytle, D. P. Miller, E. R. Rosenkranz, H. M. Lever, and D. M. Cosgrove Surgical management of hypertrophic obstructive cardiomyopathy:Early and late results J. Thorac. Cardiovasc. Surg., July 1, 1995; 110(1): 195 - 208. [Abstract] [Full Text]

				M. D. Winniford, J. T. Willerson, and L. D. Hillis Calcium Antagonists in the Treatment of Individuals with Ischemic Heart Disease Angiology, August 1, 1982; 33(8): 522 - 539. [Abstract] [PDF]